Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


June 02, 2015 12:36 PM ET

Pharmaceuticals

Company Overview of Merck Sharp & Dohme B.V.

Company Overview

Merck Sharp & Dohme B.V. produces, packs, and sends medicines to more than 140 countries. The company produces medicines for diabetes, high blood pressure, migraines, high cholesterol, osteoporosis, pain, and rheumatic diseases. Merck Sharp & Dohme B.V. was founded in 1954 and is based in Haarlem, the Netherlands. Merck Sharp & Dohme B.V. operates as a subsidiary of Merck & Co. Inc.

Waarderweg 39

Haarlem,  2031

Netherlands

Founded in 1954

Phone:

31 23 515 3153

Fax:

31 23 514 8000

Key Executives for Merck Sharp & Dohme B.V.

Managing Director
Compensation as of Fiscal Year 2014.

Merck Sharp & Dohme B.V. Key Developments

Forest Laboratories Holdings Limited Partners with Merck Sharp & Dohme B.V

Forest Laboratories Holdings Limited has agreed to partner with Merck Sharp & Dohme B.V., under which, Forest Laboratories will acquire from Merck the exclusive marketing rights in the US for Saphris(R) (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania. Under the terms of the agreement, Forest Laboratories will make an upfront payment of $240 million and additional payments to Merck based on defined sales milestones. As a part of the agreement, Merck will responsible for product supply. Forest Laboratories will responsible for continued commercialization, including completing certain post marketing studies of Saphris following a transition period, and will be the marketing authorization holder. The agreement is expected to close in early 2014 pending regulatory review and satisfaction of all closing conditions. The transaction will allow Forest Laboratories to gain access to another commercial product in the central nervous system (CNS) category, and also gives access to the schizophrenia segment to work towards registering and commercializing cariprazine. It will also allow Merck to focus on both research and development (R&D) and commercial resources on other opportunities, while complementing Forest Laboratories' product portfolio and allowing for continued access to Saphris for physicians and patients.

Similar Private Companies By Industry

Company Name Region
BioClin B.V. Europe
CyTuVax B.V. Europe
Artu Biologicals Europe B.V. Europe
Farallone Therapeutics B.V. Europe
Diosynth B.V. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Merck Sharp & Dohme B.V., please visit www.msd.nl. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.